Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on Arcus Biosciences (NYSE:RCUS) and raises the price target from $41 to $44.
August 24, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup maintains a 'Buy' rating on Arcus Biosciences and raises the price target from $41 to $44, which could potentially increase investor confidence and drive the stock price up in the short term.
The 'Buy' rating maintained by Citigroup indicates a positive outlook for Arcus Biosciences. The increase in price target from $41 to $44 suggests that the analyst believes the stock has potential for further growth. This could increase investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100